Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald de Wit

Showing results (141-150 of 175) with videos related to

Pageof 18
Sort By:
The Journal of Molecular Diagnostics : JMD|February 24, 2018
An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor CellsAnieta M Sieuwerts, Bianca Mostert, Michelle van der Vlugt-Daane, et al.
European Urology|July 20, 2015
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor CellsWendy Onstenk, Anieta M Sieuwerts, Jaco Kraan, et al.
JAMA Oncology|August 26, 2016
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail StudyEllen S de Morrée, Nicholas J Vogelzang, Daniel P Petrylak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1Matthew Smith, Johann De Bono, Cora Sternberg, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2014
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus PanelJohn M Fitzpatrick, Joaquim Bellmunt, Karim Fizazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular CancerJoost M Blok, Harmke J Groot, Eline H Huele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 StudyEmmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, et al.
Clinical Genitourinary Cancer|December 1, 2021
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alfons J M van den Eertwegh, et al.
European Urology|January 28, 2022
Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial CarcinomaJ Alberto Nakauma-González, Maud Rijnders, Job van Riet, et al.
Molecular Oncology|March 14, 2025
Cell-free DNA aneuploidy score as a dynamic early response marker in prostate cancerKhrystany T Isebia, Anouk C de Jong, Lisanne F van Dessel, et al.
Pageof 18

Showing results (141-150 of 175) with videos related to

Sort By:
Pageof 18
The Journal of Molecular Diagnostics : JMD|February 24, 2018
An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor CellsAnieta M Sieuwerts, Bianca Mostert, Michelle van der Vlugt-Daane, et al.
European Urology|July 20, 2015
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor CellsWendy Onstenk, Anieta M Sieuwerts, Jaco Kraan, et al.
JAMA Oncology|August 26, 2016
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail StudyEllen S de Morrée, Nicholas J Vogelzang, Daniel P Petrylak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1Matthew Smith, Johann De Bono, Cora Sternberg, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2014
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus PanelJohn M Fitzpatrick, Joaquim Bellmunt, Karim Fizazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular CancerJoost M Blok, Harmke J Groot, Eline H Huele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 StudyEmmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, et al.
Clinical Genitourinary Cancer|December 1, 2021
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alfons J M van den Eertwegh, et al.
European Urology|January 28, 2022
Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial CarcinomaJ Alberto Nakauma-González, Maud Rijnders, Job van Riet, et al.
Molecular Oncology|March 14, 2025
Cell-free DNA aneuploidy score as a dynamic early response marker in prostate cancerKhrystany T Isebia, Anouk C de Jong, Lisanne F van Dessel, et al.
Pageof 18